Literature DB >> 7094936

Variability of serum indomethacin concentrations after oral and intravenous administration to preterm infants.

R Mrongovius, H Imbeck, L Wille, H Müller, H W Seyberth.   

Abstract

Fifteen preterm infants with patent ductus arteriosus and respiratory distress syndrome were given indomethacin (0.2 mg/kg) at 12 h intervals up to three times, either orally or intravenously, in an uncontrolled, non-randomized study. Serum indomethacin concentrations were determined in blood samples taken 12 h after dosing. There was considerable variability in the serum indomethacin concentrations, especially after oral administration, although the mean concentrations after each of the three doses were similar after both oral and intravenous administration. The frequency of closures and transient closures of the ductus arteriosus was also similar for both routes of administration. There was, however, no relation between concentration and effect in individual patients. The sustained exposure to indomethacin which appears to be necessary for ductal closure can sometimes be attained by oral administration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7094936     DOI: 10.1007/BF00441143

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  18 in total

1.  Recovery of prostaglandin production associated with reopening of the ductus arteriosus after indomethacin treatment in preterm infants with respiratory distress syndrome.

Authors:  H W Seyberth; H Müller; L Wille; H Plückthun; D Wolf; H E Ulmer
Journal:  Pediatr Pharmacol (New York)       Date:  1982

2.  Patent ductus and indomethacin.

Authors: 
Journal:  Lancet       Date:  1981-04-18       Impact factor: 79.321

3.  Mass spectrometric determination of urinary prostaglandins in preterm infants. The basis for an effective and safe therapeutic regimen for the pharmacological closure.

Authors:  H W Seyberth; H Müller; T Erlenmaier; R Mrongovius
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

4.  Effectiveness and pharmacokinetics of indomethacin in premature newborns with patent ductus arteriosus.

Authors:  P Vert; G Bianchetti; F Marchal; P Monin; P L Morselli
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

5.  Plasma indomethacin levels in preterm newborn infants with symptomatic patent ductus arteriosus--clinical and echocardiographic assessments of response.

Authors:  B S Alpert; M J Lewins; D W Rowland; M J Grant; P M Olley; S J Soldin; P R Swyer; F Coceani; R D Rowe
Journal:  J Pediatr       Date:  1979-10       Impact factor: 4.406

6.  Gestational age and indomethacin elimination in the neonate.

Authors:  M A Evans; R Bhat; D Vidyasagar; M Vadapalli; E Fisher; A Hastreiter
Journal:  Clin Pharmacol Ther       Date:  1979-12       Impact factor: 6.875

7.  Pharmacokinetics of indomethacin in the premature infant.

Authors:  G Bianchetti; P Monin; F Marchal; C Dubruc; M J Boutroy; P L Morselli; P Vert
Journal:  Dev Pharmacol Ther       Date:  1980

8.  Serum indomethacin concentrations after intravenous administration to preterm infants with patent ductus arteriosus.

Authors:  S Petersen; N C Christensen; K Møller Jensen; E Ryssing
Journal:  Acta Paediatr Scand       Date:  1981-09

9.  A comparison of oral and intravenous indomethacin dispositions in the premature infant with patent ductus arteriosus.

Authors:  M Evans; R Bhat; D Vidyasagar; M Patel; A Hastreiter
Journal:  Pediatr Pharmacol (New York)       Date:  1981

10.  Furosemide use in premature infants and appearance of patent ductus arteriosus.

Authors:  T P Green; T R Thompson; D Johnson; J E Lock
Journal:  Am J Dis Child       Date:  1981-03
View more
  2 in total

1.  Introduction of plasma indomethacin level monitoring and evaluation of an effective threshold level in very low birth weight infants with symptomatic patent ductus arteriosus.

Authors:  H W Seyberth; G Knapp; D Wolf; H E Ulmer
Journal:  Eur J Pediatr       Date:  1983-12       Impact factor: 3.183

Review 2.  Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.

Authors:  Sindhu Sivanandan; Ramesh Agarwal
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.